SCHEMBL3784071

SCHEMBL3784071

COC(=O)[C@@H]1C[C@@H](F)CN1C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
FKBP1A P62942 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
PREP P48147 2/20 0.45
MITF O75030 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
HTR2C P28335 1/20 0.44
CPB1 P15086 1/20 0.44
PEPD P12955 1/20 0.44
XPNPEP1 Q9NQW7 1/20 0.44
ALDH1A1 P00352 2/20 0.43
CYP3A4 P08684 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245807 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL4245806 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL3793417 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL3788934 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL1336271 1.00 POLB (0.49) POLBFKBP1ANPSR1PREPMITF
SCHEMBL21874256 0.87 NPC1 (0.49) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL1150913 0.87 NPC1 (0.49) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL9940046 0.87 NPC1 (0.49) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL11450804 0.87 NPC1 (0.49) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL2499400 0.87 NPC1 (0.49) POLBNPC1RAB9ASMN1; SMN2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2025-05-01 US disclosed
CN-119156383-A Selective KRAS G12C inhibitors and uses thereof 1200药业有限责任公司 2024-12-17 CN disclosed
WO-2023086383-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2023-05-19 WO disclosed
US-20100174096-A1 Methods for Production of Optically Active Fluoropyrrolidine Derivatives IM&T RESEARCH, INC. (US) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS POLB 1870/4885FKBP1A 1508/4885NPSR1 4792/4885
US-20100174096-A1 Methods for Production of Optically Active Fluoropyrrolidine Derivatives QDPR, FDPS, DPYD POLB 1745/4885FKBP1A 2321/4885NPSR1 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.